A nem szteroid gyulladáscsökkento okozta gastropathia A megelozés újabb szempontjai

Translated title of the contribution: NSAID-associated gastropathy: Recent aspects of prevention

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs world-wide. Gastroduodenal ulcers are found at endoscopy in 15 to 30% of patients who use NSAIDs regularly. The annual incidence of severe upper gastrointestinal complications such as bleeding or perforation is 1.0 to 1.5%. From a cost-benefit perspective, prevention strategies should consider both gastrointestinal, and recently, cardiovascular risk factors. No prophylaxis is necessary with low gastrointestinal risk. There are currently four possible strategies to reduce the risk of adverse gastrointestinal effects: 1. the use of selective COX-2 inhibitors or coxibs rather than traditional NSAIDs; 2. co-therapy, primarily with proton pump inhibitors, to ensure protection to gastric mucous membrane; 3. co-therapy with a coxib and a proton pump inhibitor in patients with very high risk (eg., history of bleeding); 4. eradication of Helicobacter pylori infection in patients with a history of ulcer. The use of coxibs decrease the risk of gastrointestinal damage by roughly 50%. In the presence of gastrointestinal risk factors or for patients on aspirin also treated with an NSAID or a coxib, protection with a proton pump inhibitor is recommended. Proton pump inhibitor therapy is also useful for the prevention and treatment of NSAID-induced dyspepsia. The beneficial effects of proton pump inhibitors cannot solely be explained by their profound antisecretory action. Therefore, several acid secretion-independent mechanisms of action have been proposed.

Original languageHungarian
Pages (from-to)275-280
Number of pages6
JournalLege Artis Medicinae
Volume17
Issue number4-5
Publication statusPublished - Apr 2007

Fingerprint

Proton Pump Inhibitors
Anti-Inflammatory Agents
Cyclooxygenase 2 Inhibitors
Pharmaceutical Preparations
Hemorrhage
Dyspepsia
Helicobacter Infections
Therapeutics
Peptic Ulcer
Helicobacter pylori
Endoscopy
Aspirin
Ulcer
Cost-Benefit Analysis
Stomach
Mucous Membrane
Acids
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A nem szteroid gyulladáscsökkento okozta gastropathia A megelozés újabb szempontjai. / Herszényi, L.

In: Lege Artis Medicinae, Vol. 17, No. 4-5, 04.2007, p. 275-280.

Research output: Contribution to journalArticle

@article{137f942be59346639865be4d67f3c421,
title = "A nem szteroid gyullad{\'a}scs{\"o}kkento okozta gastropathia A megeloz{\'e}s {\'u}jabb szempontjai",
abstract = "Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs world-wide. Gastroduodenal ulcers are found at endoscopy in 15 to 30{\%} of patients who use NSAIDs regularly. The annual incidence of severe upper gastrointestinal complications such as bleeding or perforation is 1.0 to 1.5{\%}. From a cost-benefit perspective, prevention strategies should consider both gastrointestinal, and recently, cardiovascular risk factors. No prophylaxis is necessary with low gastrointestinal risk. There are currently four possible strategies to reduce the risk of adverse gastrointestinal effects: 1. the use of selective COX-2 inhibitors or coxibs rather than traditional NSAIDs; 2. co-therapy, primarily with proton pump inhibitors, to ensure protection to gastric mucous membrane; 3. co-therapy with a coxib and a proton pump inhibitor in patients with very high risk (eg., history of bleeding); 4. eradication of Helicobacter pylori infection in patients with a history of ulcer. The use of coxibs decrease the risk of gastrointestinal damage by roughly 50{\%}. In the presence of gastrointestinal risk factors or for patients on aspirin also treated with an NSAID or a coxib, protection with a proton pump inhibitor is recommended. Proton pump inhibitor therapy is also useful for the prevention and treatment of NSAID-induced dyspepsia. The beneficial effects of proton pump inhibitors cannot solely be explained by their profound antisecretory action. Therefore, several acid secretion-independent mechanisms of action have been proposed.",
keywords = "Aspirin, Coxib, Nonsteroidal anti-inflammatory drugs (NSAIDs), Proton pump inhibitor",
author = "L. Hersz{\'e}nyi",
year = "2007",
month = "4",
language = "Hungarian",
volume = "17",
pages = "275--280",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "4-5",

}

TY - JOUR

T1 - A nem szteroid gyulladáscsökkento okozta gastropathia A megelozés újabb szempontjai

AU - Herszényi, L.

PY - 2007/4

Y1 - 2007/4

N2 - Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs world-wide. Gastroduodenal ulcers are found at endoscopy in 15 to 30% of patients who use NSAIDs regularly. The annual incidence of severe upper gastrointestinal complications such as bleeding or perforation is 1.0 to 1.5%. From a cost-benefit perspective, prevention strategies should consider both gastrointestinal, and recently, cardiovascular risk factors. No prophylaxis is necessary with low gastrointestinal risk. There are currently four possible strategies to reduce the risk of adverse gastrointestinal effects: 1. the use of selective COX-2 inhibitors or coxibs rather than traditional NSAIDs; 2. co-therapy, primarily with proton pump inhibitors, to ensure protection to gastric mucous membrane; 3. co-therapy with a coxib and a proton pump inhibitor in patients with very high risk (eg., history of bleeding); 4. eradication of Helicobacter pylori infection in patients with a history of ulcer. The use of coxibs decrease the risk of gastrointestinal damage by roughly 50%. In the presence of gastrointestinal risk factors or for patients on aspirin also treated with an NSAID or a coxib, protection with a proton pump inhibitor is recommended. Proton pump inhibitor therapy is also useful for the prevention and treatment of NSAID-induced dyspepsia. The beneficial effects of proton pump inhibitors cannot solely be explained by their profound antisecretory action. Therefore, several acid secretion-independent mechanisms of action have been proposed.

AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs world-wide. Gastroduodenal ulcers are found at endoscopy in 15 to 30% of patients who use NSAIDs regularly. The annual incidence of severe upper gastrointestinal complications such as bleeding or perforation is 1.0 to 1.5%. From a cost-benefit perspective, prevention strategies should consider both gastrointestinal, and recently, cardiovascular risk factors. No prophylaxis is necessary with low gastrointestinal risk. There are currently four possible strategies to reduce the risk of adverse gastrointestinal effects: 1. the use of selective COX-2 inhibitors or coxibs rather than traditional NSAIDs; 2. co-therapy, primarily with proton pump inhibitors, to ensure protection to gastric mucous membrane; 3. co-therapy with a coxib and a proton pump inhibitor in patients with very high risk (eg., history of bleeding); 4. eradication of Helicobacter pylori infection in patients with a history of ulcer. The use of coxibs decrease the risk of gastrointestinal damage by roughly 50%. In the presence of gastrointestinal risk factors or for patients on aspirin also treated with an NSAID or a coxib, protection with a proton pump inhibitor is recommended. Proton pump inhibitor therapy is also useful for the prevention and treatment of NSAID-induced dyspepsia. The beneficial effects of proton pump inhibitors cannot solely be explained by their profound antisecretory action. Therefore, several acid secretion-independent mechanisms of action have been proposed.

KW - Aspirin

KW - Coxib

KW - Nonsteroidal anti-inflammatory drugs (NSAIDs)

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=34249895328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249895328&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34249895328

VL - 17

SP - 275

EP - 280

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 4-5

ER -